Serotonin Toxicity Versus Withdrawal: Clonidine One Size Fits All?

Area of Science:

• Neonatal pharmacology
• Developmental toxicology
• Pediatric neurology

Background:

• Serotonin discontinuation syndrome (SDS) presents challenges in managing infants exposed to maternal psychotropic medications.
• Existing pharmacologic management strategies for SDS lack established consensus.
• Maternal antidepressant use during pregnancy can lead to neonatal adaptation issues.

Purpose of the Study:

• To report the successful use of clonidine in managing a term infant with poor neonatal adaptation.
• To describe the biphasic symptoms of serotonin toxicity and subsequent withdrawal in a neonate.
• To document the efficacy of clonidine in treating severe neonatal symptoms associated with maternal antidepressant exposure.

Main Methods:

• A term infant exposed to multiple maternal antidepressants (sertraline, trazodone, venlafaxine, buspirone) was assessed.
• The infant presented with symptoms of acute toxicity followed by withdrawal, necessitating intervention.
• Clonidine was administered and titrated from 1 mcg/kg/dose to 4 mcg/kg/dose every 3 hours to manage symptoms.

Main Results:

• The infant exhibited severe hypertonia, tremors, hypoglycemia, and feeding difficulties.
• Modified Finnegan Neonatal Abstinence scores were significantly elevated, indicating severe withdrawal.
• Clonidine administration successfully controlled the infant's hypertonia, tremors, and other withdrawal symptoms.

Conclusions:

• Clonidine can be an effective treatment for serotonin discontinuation syndrome and neonatal withdrawal.
• This case demonstrates the utility of clonidine in managing complex neonatal adaptation issues related to maternal antidepressant use.
• Further research is warranted to establish standardized protocols for clonidine use in neonatal abstinence syndromes.